Generated by AI
Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness. Its lead candidate is being evaluated in clinical studies as a capsule formulation of naturally sourced psilocybin, reflecting the company’s emphasis on standardized, non-synthetic drug development. Psyence Biomedical operates within the broader life sciences and healthcare markets, combining drug development, clinical research, and commercialization efforts around psychedelic medicine. Through this specialization, the company occupies a niche position in the emerging field of evidence-based psychedelic therapeutics, with a focus on supportive care applications rather than general consumer health products.
Website121 Richmond Street West
Toronto, ON, M5H 2K1
Canada
The latest articles about PBM.
Ibogaine regulatory readiness pack completed and U.S. cGMP manufacturing agreement concluded with DEA-registered Benuvia in Texas; investment supports PsyLabs’ intended supply of pharmaceutical-grade ibogaine for the planned U.S. development programNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. (“PsyLabs”) have been achi
Summary of Sep 14's posts. Generated by AI.
Summary of Apr 29's posts. Generated by AI.
Summary of Aug 18's posts. Generated by AI.
Investors talking about PBM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.